Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bicara Therapeutics Inc. Common Stock (BCAX)
USD28.35
+0.20 (+0.71%)
US NASDAQ Healthcare Biotechnology
Address
116 Huntington Avenue 2116
Boston, MA, US
Boston, MA, US
CEO
Claire Mazumdar Clemon
Website
bicara.com
IPO
2024-09-13
CIK 2023658 ISIN US0554771032
Description
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD28.35
+0.20 (+0.71%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
663.3K
Beta
-0.81
Float Shares
35.26M
Free Float %
64.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.36% | -2.99% | +1.08% | +57.49% | +56.94% | +32.98% | +71.63% | -4.40% | -4.40% | -4.40% | -4.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
28.35
Low
18.00
-36.5%
Consensus
28.60
+0.9%
Median
28.00
-1.2%
High
42.00
+48.1%
DCF (Unlevered)
1.64
-94.2%
DCF (Levered)
1.74
-93.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
77% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 8 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
42.00
+48.1%
|
| Last Quarter | 1 |
42.00
+48.1%
|
| Last Year | 6 |
25.00
-11.8%
|
| All Time | 8 |
29.13
+2.8%
|
Quality scores
Altman Z-Score
18.04
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-101.6% Q1'26: -36.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.5% ★ Q1'26: +11.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 EPS Ana. |
Dec 2027 8 EPS Ana. |
Dec 2028 9 Rev. Ana. 9 EPS Ana. |
Dec 2029 4 Rev. Ana. 3 EPS Ana. |
Dec 2030 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
—
— – —
|
41.51M
41.51M – 41.51M
|
197.27M
197.27M – 197.27M
+375.3% YoY
|
509.12M
509.12M – 509.12M
+158.1% YoY
|
| EBITDA |
-82.33M
|
-155.60M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-82.39M
|
-155.60M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-68.00M
est: -92.33M (+26.4%)
|
-137.95M
est: -137.95M (+0.0%)
|
-192.86M
-234.47M – -162.58M
-39.8% YoY
|
-228.41M
-233.40M – -169.98M
-18.4% YoY
|
-238.39M
-244.11M – -129.17M
-4.4% YoY
|
-143.80M
-143.80M – -143.80M
+39.7% YoY
|
62.42M
62.42M – 62.42M
+143.4% YoY
|
| SGA |
18.77M
|
30.51M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.25
est: -2.42 (+48.3%)
|
-2.52
est: -2.52 (-0.2%)
|
-3.34
-4.29 – -2.97
-32.8% YoY
|
-3.63
-4.27 – -3.11
-8.6% YoY
|
-3.43
-4.46 – -2.36
+5.5% YoY
|
-2.63
-2.63 – -2.63
+23.4% YoY
|
1.14
1.14 – 1.14
+143.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
34
Total invested
100.96M
Insider transactions (90d)
4
Beneficial owners (>5%)
14
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peter Kolchinsky | 6.96M | 12.80% | — | 6.96M | — | 10.00 | HC, IN | United States | 2024-09-23 | ↗ |
| 2 | RA Capital Management, L.P. | 6.96M | 12.80% | — | 6.96M | — | 10.00 | IA, PN | Delaware | 2024-09-23 | ↗ |
| 3 | Rajeev Shah | 6.96M | 12.80% | — | 6.96M | — | 10.00 | HC, IN | United States | 2024-09-23 | ↗ |
| 4 | RA Capital Healthcare Fund, L.P. | 4.30M | 7.90% | — | 4.30M | — | 10.00 | PN | Delaware | 2024-09-23 | ↗ |
| 5 | Heath Lukatch | 3.17M | 5.80% | — | 3.17M | — | — | IN | Delaware | 2024-09-26 | ↗ |
| 6 | Red Tree GP, LLC | 3.17M | 5.80% | — | 3.17M | — | — | OO | Delaware | 2024-09-26 | ↗ |
| 7 | Red Tree Venture Fund, L.P. | 3.17M | 5.80% | — | 3.17M | — | — | PN | Delaware | 2024-09-26 | ↗ |
| 8 | David Bonderman | 3.01M | 5.50% | — | 3.01M | — | — | IN | United States of America | 2024-09-18 | ↗ |
| 9 | James G. Coulter | 3.01M | 5.50% | — | 3.01M | — | — | IN | United States of America | 2024-09-18 | ↗ |
| 10 | Jon Winkelried | 3.01M | 5.50% | — | 3.01M | — | — | IN | United States of America | 2024-09-18 | ↗ |
| 11 | TPG GP A, LLC | 3.01M | 5.50% | — | 3.01M | — | — | OO | Delaware | 2024-09-18 | ↗ |
| 12 | Abigail P. Johnson | 2.50M | 5.10% | — | — | 2.50M | — | IN | Delaware | 2024-09-18 | ↗ |
| 13 | FMR LLC | 2.50M | 5.10% | 2.50M | — | 2.50M | — | HC | Delaware | 2024-09-18 | ↗ |
| 14 | 13G | 31.5K | 0.10% | 31.5K | — | 31.5K | — | OO | Bermuda | 2024-09-26 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
34
-110 vs prev Q
New positions
7
Closed positions
113
Increased
21
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 15.7K +15.7K (+100.0%) | 263.44M +263.4M (+100.0%) | 0.03% +0.029 pp | 0.10% +0.104 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 6.96M +— (+0.0%) | 117.07M +7.2M (+6.6%) | 12.75% -0.006 pp | 1.20% -0.154 pp | USD25.47 -33.9% | 6 qtrs — |
| 3 | SIREN, L.L.C. | 5.22M +— (+0.0%) | 87.80M +5.4M (+6.6%) | 9.56% -0.004 pp | 2.62% -0.603 pp | USD19.11 -11.9% | 6 qtrs — |
| 4 | VESTAL POINT CAPITAL, LP | 3.58M -1.5M (-29.9%) | 60.17M -20.4M (-25.3%) | 6.55% -2.799 pp | 2.05% -1.591 pp | USD12.73 +32.2% | 6 qtrs — |
| 5 | FMR LLC | 3.35M +648.9K (+24.0%) | 56.33M +13.7M (+32.2%) | 6.13% +1.187 pp | 0.00% +0.001 pp | USD19.43 -13.4% | 6 qtrs — |
| 6 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 3.24M +2.8M (+596.5%) | 54.47M +47.1M (+642.2%) | 5.93% +5.080 pp | 0.03% +0.030 pp | USD16.68 +0.9% | 2 qtrs — |
| 7 | RED TREE MANAGEMENT, LLC | 3.17M +— (+0.0%) | 53.36M +3.3M (+6.6%) | 5.81% -0.003 pp | 48.94% -11.443 pp | USD17.42 -3.4% | 5 qtrs — |
| 8 | TPG GP A, LLC | 3.01M +— (+0.0%) | 50.67M +3.1M (+6.6%) | 5.52% -0.003 pp | 1.89% -0.703 pp | USD25.47 -33.9% | 6 qtrs — |
| 9 | JANUS HENDERSON GROUP PLC | 2.65M +2.6M (+100.0%) | 44.48M +44.5M (+100.0%) | 4.85% +4.850 pp | 0.02% +0.020 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 10 | DEEP TRACK CAPITAL, LP | 2.61M +187.3K (+7.7%) | 43.99M +5.7M (+14.8%) | 4.79% +0.341 pp | 0.78% -0.285 pp | USD18.50 -9.0% | 6 qtrs — |
| 11 | BLACKROCK, INC. | 2.53M +216.7K (+9.4%) | 42.55M +6.1M (+16.6%) | 4.63% +0.395 pp | 0.00% +0.000 pp | USD14.63 +15.0% | 5 qtrs — |
| 12 | OMEGA FUND MANAGEMENT, LLC | 2.20M +— (+0.0%) | 37.10M +2.3M (+6.6%) | 4.04% -0.002 pp | 12.95% -2.705 pp | USD25.47 -33.9% | 6 qtrs — |
| 13 | VANGUARD GROUP INC | 2.19M -14.8K (-0.7%) | 36.79M +2.0M (+5.9%) | 4.01% -0.029 pp | 0.00% +0.000 pp | USD14.15 +18.9% | 6 qtrs — |
| 14 | STATE STREET CORP | 1.65M +1.1M (+179.5%) | 27.76M +18.4M (+197.9%) | 3.02% +1.941 pp | 0.00% +0.001 pp | USD15.98 +5.3% | 5 qtrs — |
| 15 | FRANKLIN RESOURCES INC | 1.62M +1.6M (+100.0%) | 27.27M +27.3M (+100.0%) | 2.97% +2.969 pp | 0.01% +0.007 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 16 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.56M -195.9K (-11.2%) | 26.25M -1.5M (-5.3%) | 2.86% -0.360 pp | 0.00% 0.000 pp | USD21.34 -21.1% | 6 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 811.4K -19.8K (-2.4%) | 13.66M +531.1K (+4.0%) | 1.49% -0.037 pp | 0.00% +0.000 pp | USD15.68 +7.3% | 6 qtrs — |
| 18 | CITADEL ADVISORS LLC | 772.3K +772.3K (+100.0%) | 13.00M +13.0M (+100.0%) | 1.42% +1.415 pp | 0.00% +0.002 pp | USD16.83 +0.0% | 3 qtrs — |
| 19 | FIL LTD | 758.5K -45.3K (-5.6%) | 12.77M +74.2K (+0.6%) | 1.39% -0.084 pp | 0.01% 0.000 pp | USD25.47 -33.9% | 6 qtrs — |
| 20 | ACORN CAPITAL ADVISORS, LLC | 643.4K +— (+0.0%) | 10.83M +669.1K (+6.6%) | 1.18% -0.001 pp | 3.67% -1.488 pp | USD17.42 -3.4% | 5 qtrs — |
| 21 | AISLING CAPITAL MANAGEMENT LP | 568.9K +— (+0.0%) | 9.57M +591.7K (+6.6%) | 1.04% -0.001 pp | 2.00% +0.031 pp | USD25.47 -33.9% | 6 qtrs — |
| 22 | GOLDMAN SACHS GROUP INC | 552.3K +319.6K (+137.3%) | 9.30M +5.6M (+152.9%) | 1.01% +0.586 pp | 0.00% +0.001 pp | USD17.49 -3.8% | 6 qtrs — |
| 23 | MILLENNIUM MANAGEMENT LLC | 434.7K -580.2K (-57.2%) | 7.32M -8.7M (-54.3%) | 0.80% -1.064 pp | 0.00% -0.004 pp | USD11.41 +47.5% | 6 qtrs — |
| 24 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 429.1K +58.4K (+15.8%) | 7.22M +1.4M (+23.4%) | 0.79% +0.107 pp | 0.37% +0.028 pp | USD23.51 -28.4% | 6 qtrs — |
| 25 | ENSIGN PEAK ADVISORS, INC | 401.4K +401.4K (+100.0%) | 6.76M +6.8M (+100.0%) | 0.74% +0.736 pp | 0.01% +0.012 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 26 | NAN FUNG TRINITY (HK) LTD | 372.4K -12.5K (-3.2%) | 6.27M +189.9K (+3.1%) | 0.68% -0.023 pp | 0.50% -0.110 pp | USD10.00 +68.3% | 3 qtrs — |
| 27 | BANK OF AMERICA CORP /DE/ | 335.7K -120.9K (-26.5%) | 5.65M -1.6M (-21.6%) | 0.62% -0.222 pp | 0.00% 0.000 pp | USD9.74 +72.8% | 6 qtrs — |
| 28 | ALGERT GLOBAL LLC | 318.3K +300.7K (+1,709.4%) | 5.36M +5.1M (+1,826.6%) | 0.58% +0.551 pp | 0.08% +0.079 pp | USD16.77 +0.4% | 2 qtrs — |
| 29 | CLEARBRIDGE INVESTMENTS, LLC | 298.8K -25.6K (-7.9%) | 5.03M -92.9K (-1.8%) | 0.55% -0.047 pp | 0.00% +0.000 pp | USD15.79 +6.6% | 2 qtrs — |
| 30 | PALO ALTO INVESTORS LP | 298.6K +298.6K (+100.0%) | 5.03M +5.0M (+100.0%) | 0.55% +0.547 pp | 0.70% +0.700 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 31 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 272.1K -8.7K (-3.1%) | 4.58M +145.2K (+3.3%) | 0.50% -0.016 pp | 0.00% +0.000 pp | USD15.75 +6.9% | 5 qtrs — |
| 32 | DAFNA CAPITAL MANAGEMENT LLC | 261.6K -55.4K (-17.5%) | 4.40M -603.0K (-12.0%) | 0.48% -0.102 pp | 1.02% -0.214 pp | USD13.25 +27.0% | 5 qtrs — |
| 33 | TD ASSET MANAGEMENT INC | 244.6K +59.6K (+32.2%) | 4.12M +1.2M (+41.0%) | 0.45% +0.109 pp | 0.00% +0.001 pp | USD17.07 -1.4% | 6 qtrs — |
| 34 | NORTHERN TRUST CORP | 237.1K -23.8K (-9.1%) | 3.99M -128.6K (-3.1%) | 0.43% -0.044 pp | 0.00% +0.000 pp | USD14.82 +13.6% | 5 qtrs — |
| 35 | WOODLINE PARTNERS LP | 232.7K -116.0K (-33.3%) | 3.92M -1.6M (-28.9%) | 0.43% -0.213 pp | 0.02% -0.011 pp | USD22.87 -26.4% | 6 qtrs — |
| 36 | ORBIMED ADVISORS LLC | 209.1K +209.1K (+100.0%) | 3.52M +3.5M (+100.0%) | 0.38% +0.383 pp | 0.07% +0.072 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 37 | UBS GROUP AG | 192.2K +94.8K (+97.4%) | 3.23M +1.7M (+110.4%) | 0.35% +0.174 pp | 0.00% +0.000 pp | USD16.16 +4.1% | 6 qtrs — |
| 38 | HUDSON BAY CAPITAL MANAGEMENT LP | 150.0K +150.0K (+100.0%) | 2.52M +2.5M (+100.0%) | 0.27% +0.275 pp | 0.01% +0.008 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 39 | D. E. SHAW & CO., INC. | 136.5K +136.5K (+100.0%) | 2.30M +2.3M (+100.0%) | 0.25% +0.250 pp | 0.00% +0.001 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 40 | DEUTSCHE BANK AG\ | 128.6K +1.2K (+0.9%) | 2.16M +152.3K (+7.6%) | 0.24% +0.002 pp | 0.00% +0.000 pp | USD16.57 +1.6% | 5 qtrs — |
| 41 | NAPEAN TRADING & INVESTMENT CO (SINGAPORE) PTE LTD | 113.8K -162.2K (-58.8%) | 1.91M -2.4M (-56.1%) | 0.21% -0.297 pp | 0.37% -0.475 pp | USD13.03 +29.2% | 4 qtrs — |
| 42 | HEALTHINVEST PARTNERS AB | 111.4K -92.4K (-45.3%) | 1.87M +1.5M (+448.7%) | 0.20% -0.170 pp | 0.60% -0.669 pp | USD13.29 +26.6% | 4 qtrs — |
| 43 | MORGAN STANLEY | 109.5K +9.4K (+9.4%) | 1.84M +262.7K (+16.6%) | 0.20% +0.017 pp | 0.00% +0.000 pp | USD14.77 +13.9% | 6 qtrs — |
| 44 | BARCLAYS PLC | 103.2K +93.2K (+932.4%) | 1.74M +1.5M (+582.2%) | 0.19% +0.171 pp | 0.00% +0.000 pp | USD16.47 +2.2% | 6 qtrs — |
| 45 | SOLEUS CAPITAL MANAGEMENT, L.P. | 100.0K +100.0K (+100.0%) | 1.68M +1.7M (+100.0%) | 0.18% +0.183 pp | 0.06% +0.062 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 46 | TWO SIGMA INVESTMENTS, LP | 98.5K +3.2K (+3.4%) | 1.66M +153.6K (+10.2%) | 0.18% +0.006 pp | 0.00% +0.000 pp | USD9.88 +70.3% | 6 qtrs — |
| 47 | BNP PARIBAS ARBITRAGE, SNC | 95.9K +59.4K (+162.6%) | 1.61M +1.0M (+179.9%) | 0.18% +0.109 pp | 0.00% +0.000 pp | USD16.36 +2.9% | 5 qtrs — |
| 48 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 98.9K -27.9K (-22.0%) | 1.60M -400.6K (-20.0%) | 0.18% -0.051 pp | 0.00% 0.000 pp | USD13.82 +21.8% | 6 qtrs — |
| 49 | BANK OF NEW YORK MELLON CORP | 88.7K +4.1K (+4.9%) | 1.49M +157.6K (+11.8%) | 0.16% +0.008 pp | 0.00% +0.000 pp | USD13.72 +22.7% | 5 qtrs — |
| 50 | JANE STREET GROUP, LLC | 85.6K +85.6K (+100.0%) | 1.44M +1.4M (+100.0%) | 0.16% +0.157 pp | 0.00% +0.000 pp | USD16.83 +0.0% | 3 qtrs — |
| 51 | CITIGROUP INC | 66.7K +66.0K (+10,067.2%) | 1.12M +1.1M (+10,737.1%) | 0.12% +0.121 pp | 0.00% +0.001 pp | USD16.83 +0.0% | 6 qtrs — |
| 52 | MARINER, LLC | 64.6K +1.9K (+3.0%) | 1.09M +97.3K (+9.8%) | 0.12% +0.003 pp | 0.00% +0.000 pp | USD14.57 +15.5% | 3 qtrs — |
| 53 | SHAY CAPITAL LLC | 64.3K +64.3K (+100.0%) | 1.08M +1.1M (+100.0%) | 0.12% +0.118 pp | 0.11% +0.112 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 54 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 60.8K +47.8K (+367.7%) | 1.02M +818.0K (+398.5%) | 0.11% +0.088 pp | 0.00% +0.000 pp | USD16.61 +1.3% | 2 qtrs — |
| 55 | Y-INTERCEPT (HONG KONG) LTD | 59.9K +59.9K (+100.0%) | 1.01M +1.0M (+100.0%) | 0.11% +0.110 pp | 0.02% +0.023 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 56 | RAFFERTY ASSET MANAGEMENT, LLC | 59.8K +59.8K (+100.0%) | 1.01M +1.0M (+100.0%) | 0.11% +0.110 pp | 0.00% +0.004 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 57 | RUSSELL INVESTMENTS GROUP, LTD. | 56.6K +17.5K (+44.7%) | 952.6K +334.8K (+54.2%) | 0.10% +0.032 pp | 0.00% +0.000 pp | USD12.96 +29.9% | 3 qtrs — |
| 58 | SCS CAPITAL MANAGEMENT LLC | 53.4K +— (+0.0%) | 899.2K +55.6K (+6.6%) | 0.10% +0.000 pp | 0.01% +0.000 pp | USD9.29 +81.2% | 3 qtrs — |
| 59 | HRT FINANCIAL LP | 50.1K +50.1K (+100.0%) | 843.0K +843.0K (+100.0%) | 0.09% +0.092 pp | 0.00% +0.003 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 60 | ALPS ADVISORS INC | 45.0K +18.6K (+70.5%) | 757.0K +340.5K (+81.7%) | 0.08% +0.034 pp | 0.00% +0.002 pp | USD12.41 +35.6% | 3 qtrs — |
| 61 | NORGES BANK | 42.9K +42.9K (+100.0%) | 721.8K +721.8K (+100.0%) | 0.08% +0.079 pp | 0.00% +0.000 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 62 | DIMENSIONAL FUND ADVISORS LP | 40.9K +40.9K (+100.0%) | 688.9K +688.9K (+100.0%) | 0.08% +0.075 pp | 0.00% +0.000 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 63 | RHUMBLINE ADVISERS | 40.6K -5.0K (-11.0%) | 683.0K -37.3K (-5.2%) | 0.07% -0.009 pp | 0.00% +0.000 pp | USD12.90 +30.5% | 5 qtrs — |
| 64 | NUVEEN, LLC | 38.8K -5.6K (-12.6%) | 653.7K -48.0K (-6.8%) | 0.07% -0.010 pp | 0.00% +0.000 pp | USD11.40 +47.6% | 4 qtrs — |
| 65 | DARK FOREST CAPITAL MANAGEMENT LP | 37.6K +37.6K (+100.0%) | 633.4K +633.4K (+100.0%) | 0.07% +0.069 pp | 0.03% +0.029 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 66 | TREXQUANT INVESTMENT LP | 37.1K -919.0 (-2.4%) | 624.3K +24.1K (+4.0%) | 0.07% -0.002 pp | 0.01% -0.001 pp | USD9.29 +81.2% | 3 qtrs — |
| 67 | WELLS FARGO & COMPANY/MN | 35.2K +9.3K (+35.9%) | 593.1K +183.8K (+44.9%) | 0.06% +0.017 pp | 0.00% +0.000 pp | USD14.40 +16.9% | 5 qtrs — |
| 68 | XTX TOPCO LTD | 34.1K -3.7K (-9.8%) | 573.3K -23.1K (-3.9%) | 0.06% -0.007 pp | 0.02% -0.016 pp | USD16.21 +3.8% | 5 qtrs — |
| 69 | SWISS NATIONAL BANK | 32.3K +32.3K (+100.0%) | 543.6K +543.6K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.000 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 70 | BLEAKLEY FINANCIAL GROUP, LLC | 29.2K -1.3K (-4.3%) | 491.1K +9.9K (+2.1%) | 0.05% -0.002 pp | 0.01% -0.003 pp | USD15.79 +6.6% | 2 qtrs — |
| 71 | ALLIANCEBERNSTEIN L.P. | 29.1K -11.7K (-28.6%) | 489.9K -153.8K (-23.9%) | 0.05% -0.021 pp | 0.00% +0.000 pp | USD9.29 +81.2% | 6 qtrs — |
| 72 | TUDOR INVESTMENT CORP ET AL | 27.4K +8.7K (+46.2%) | 461.0K +165.2K (+55.9%) | 0.05% +0.016 pp | 0.00% +0.000 pp | USD16.12 +4.4% | 2 qtrs — |
| 73 | AMERICAN CENTURY COMPANIES INC | 24.5K +13.8K (+129.4%) | 412.2K +243.6K (+144.5%) | 0.04% +0.025 pp | 0.00% +0.000 pp | USD13.54 +24.3% | 3 qtrs — |
| 74 | CAPTION MANAGEMENT, LLC | 23.0K +23.0K (+100.0%) | 387.1K +387.1K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.003 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 75 | PROFUND ADVISORS LLC | 22.2K +22.2K (+100.0%) | 373.2K +373.2K (+100.0%) | 0.04% +0.041 pp | 0.01% +0.011 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 76 | CREATIVE PLANNING | 21.8K +11.8K (+117.4%) | 367.5K +208.9K (+131.7%) | 0.04% +0.022 pp | 0.00% +0.000 pp | USD16.35 +2.9% | 2 qtrs — |
| 77 | METLIFE INVESTMENT MANAGEMENT, LLC | 21.5K +— (+0.0%) | 362.2K +22.4K (+6.6%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD15.79 +6.6% | 5 qtrs — |
| 78 | INVESCO LTD. | 21.0K +3.6K (+20.6%) | 353.5K +78.6K (+28.6%) | 0.04% +0.007 pp | 0.00% +0.000 pp | USD16.52 +1.9% | 5 qtrs — |
| 79 | JUMP FINANCIAL, LLC | 21.0K +21.0K (+100.0%) | 353.2K +353.2K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.004 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 80 | VOYA INVESTMENT MANAGEMENT LLC | 18.2K +18.2K (+100.0%) | 306.2K +306.2K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 81 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 18.1K +2.0K (+12.6%) | 302.8K +48.4K (+19.0%) | 0.03% +0.004 pp | 0.00% +0.000 pp | USD14.42 +16.7% | 5 qtrs — |
| 82 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 17.2K +15.0K (+701.4%) | 288.8K +255.0K (+754.2%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD16.57 +1.6% | 5 qtrs — |
| 83 | GROUP ONE TRADING, L.P. | 16.9K +16.9K (+100.0%) | 284.7K +284.7K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.001 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 84 | JPMORGAN CHASE & CO | 16.8K -8.1K (-32.4%) | 283.5K -110.2K (-28.0%) | 0.03% -0.015 pp | 0.00% +0.000 pp | USD15.81 +6.5% | 6 qtrs — |
| 85 | AMERIPRISE FINANCIAL INC | 16.0K +50.0 (+0.3%) | 269.8K +17.5K (+6.9%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD9.31 +80.8% | 3 qtrs — |
| 86 | LEGAL & GENERAL GROUP PLC | 16.0K +12.8K (+405.6%) | 268.6K +218.7K (+438.9%) | 0.03% +0.024 pp | 0.00% +0.000 pp | USD16.32 +3.1% | 5 qtrs — |
| 87 | QUANTINNO CAPITAL MANAGEMENT LP | 15.2K +4.6K (+43.4%) | 255.2K +88.2K (+52.8%) | 0.03% +0.008 pp | 0.00% +0.000 pp | USD16.10 +4.5% | 2 qtrs — |
| 88 | VIRTUS INVESTMENT ADVISERS, INC. | 14.4K +4.6K (+46.4%) | 242.3K +87.0K (+56.0%) | 0.03% +0.008 pp | 0.07% +0.021 pp | USD14.56 +15.6% | 4 qtrs — |
| 89 | LPL FINANCIAL LLC | 14.3K -14.0 (-0.1%) | 240.4K +14.6K (+6.5%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD15.79 +6.6% | 2 qtrs — |
| 90 | ASCENT GROUP, LLC | 14.2K +221.0 (+1.6%) | 238.2K +18.2K (+8.3%) | 0.03% +0.000 pp | 0.01% +0.000 pp | USD15.81 +6.5% | 2 qtrs — |
| 91 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 14.1K +14.1K (+100.0%) | 237.6K +237.6K (+100.0%) | 0.03% +0.026 pp | 0.00% +0.003 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 92 | INTECH INVESTMENT MANAGEMENT LLC | 14.1K +65.0 (+0.5%) | 237.4K +15.7K (+7.1%) | 0.03% +0.000 pp | 0.00% +0.000 pp | USD11.58 +45.3% | 4 qtrs — |
| 93 | ADAR1 CAPITAL MANAGEMENT, LLC | 13.7K +— (+0.0%) | 230.7K +14.3K (+6.6%) | 0.03% +0.000 pp | 0.02% -0.003 pp | USD9.29 +81.2% | 3 qtrs — |
| 94 | GRAHAM CAPITAL MANAGEMENT, L.P. | 13.1K +13.1K (+100.0%) | 220.7K +220.7K (+100.0%) | 0.02% +0.024 pp | 0.01% +0.005 pp | USD16.83 +0.0% | 1 qtrs NEW |
| 95 | BRINKER CAPITAL INVESTMENTS, LLC | 11.3K -25.0 (-0.2%) | 189.8K +11.3K (+6.4%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD15.79 +6.6% | 2 qtrs — |
| 96 | LETKO, BROSSEAU & ASSOCIATES INC | 11.2K +11.2K (+100.0%) | 188.1K +188.1K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.003 pp | USD16.83 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 92 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Innovator IBD Breakout Opportunities ETF BOUT | 7.00% | 1.10M | 0.80% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.97% | 2.06M | 0.50% |
| 3 | Virtus Biotech Clinical Trials ETF BBC | 0.82% | 472.3K | 0.65% |
| 4 | Global X - S&P Biotech ETF CURE.AX | 0.29% | 105.8K | 0.45% |
| 5 | State Street SPDR S&P Biotech ETF XBI | 0.29% | 31.79M | 0.35% |
| 6 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.13% | 604.6K | 0.40% |
| 7 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.13% | 97.6K | 0.19% |
| 8 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.13% | 94.6K | 0.35% |
| 9 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.13% | 1.41M | 0.35% |
| 10 | Innovator U.S. Small Cap Managed Floor ETF RFLR | 0.09% | 79.2K | 0.89% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.58
Neutral
Ratio by volume
0.59
Neutral
Buys
7
Sells
12
Shares acquired
60.5K
Shares disposed
102.7K
Cash buys
—
Cash sales
5.00
Net activity
-42,200
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | Raben David | Officer | M-Exempt | A | Common Stock | 5,500 | 3.79 | 20.8K | 60,786 | D | ↗ |
| 2026-04-21 | Hyep Ivan | Officer | M-Exempt | A | Common Stock | 9,200 | 3.79 | 34.9K | 154,555 | D | ↗ |
| 2026-04-20 | Mazumdar Claire | Director / Officer | M-Exempt | A | Common Stock | 15,000 | 3.79 | 56.8K | 377,152 | D | ↗ |
| 2026-04-16 | Mazumdar Claire | Director / Officer | M-Exempt | A | Common Stock | 7,080 | 5.45 | 38.6K | 362,152 | D | ↗ |
| 2026-04-15 | Cohlhepp Ryan | Director / Officer | S-Sale | D | Common Stock | 8,000 | 23.01 | 184.1K | 200,641 | D | ↗ |
| 2026-03-25 | Raben David | Officer | M-Exempt | A | Common Stock | 5,500 | 3.79 | 20.8K | 60,786 | D | ↗ |
| 2026-03-23 | Hyep Ivan | Officer | M-Exempt | A | Common Stock | 9,200 | 3.79 | 34.9K | 154,555 | D | ↗ |
| 2026-03-20 | Mazumdar Claire | Director / Officer | S-Sale | D | Common Stock | 1,596 | 18.95 | 30.2K | 339,392 | D | ↗ |
| 2026-03-19 | Mazumdar Claire | Director / Officer | S-Sale | D | Common Stock | 6,905 | 18.78 | 129.7K | 339,392 | D | ↗ |
| 2026-03-18 | Mazumdar Claire | Director / Officer | M-Exempt | A | Common Stock | 6,499 | 3.79 | 24.6K | 345,891 | D | ↗ |
| 2026-03-16 | Cohlhepp Ryan | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,000 | 3.79 | 30.3K | 117,334 | D | ↗ |
| 2026-03-06 | Mazumdar Claire | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,817 | 3.79 | 14.5K | 227,873 | D | ↗ |
| 2026-03-05 | Mazumdar Claire | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,786 | 3.79 | 6.8K | 231,690 | D | ↗ |
| 2026-03-04 | Raben David | Officer | S-Sale | D | Common Stock | 16,300 | 18.52 | 301.9K | 55,286 | D | ↗ |
| 2026-03-04 | Mazumdar Claire | Director / Officer | S-Sale | D | Common Stock | 2,631 | 18.73 | 49.3K | 339,392 | D | ↗ |
| 2026-03-04 | Hyep Ivan | Officer | M-Exempt | A | Common Stock | 2,963 | 3.79 | 11.2K | 148,318 | D | ↗ |
| 2026-03-03 | Raben David | Officer | M-Exempt | A | Common Stock | 200 | 3.79 | 757.96 | 55,486 | D | ↗ |
| 2026-03-03 | Hyep Ivan | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,318 | 3.79 | 27.7K | 58,144 | D | ↗ |
| 2026-03-03 | Cohlhepp Ryan | Director / Officer | S-Sale | D | Common Stock | 4,500 | 18.16 | 81.7K | 205,141 | D | ↗ |
| 2026-02-26 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 300,000 | 16.00 | 4.80M | 4,603,418 | I | ↗ |
| 2026-02-25 | Cohlhepp Ryan | Director / Officer | M-Exempt | A | Common Stock | 3,108 | 3.79 | 11.8K | 213,272 | D | ↗ |
| 2026-02-02 | Raben David | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 16.76 | 1.68M | 100,000 | D | ↗ |
| 2026-02-02 | Meisner Lara | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 16.76 | 1.51M | 90,000 | D | ↗ |
| 2026-02-02 | Mazumdar Claire | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 450,000 | 16.76 | 7.54M | 450,000 | D | ↗ |
| 2026-02-02 | Hyep Ivan | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 16.76 | 2.10M | 125,000 | D | ↗ |
| 2026-02-02 | Cohlhepp Ryan | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 16.76 | 5.03M | 300,000 | D | ↗ |
| 2026-01-22 | Hyep Ivan | Officer | S-Sale | D | Common Stock | 1,882 | 18.15 | 34.2K | 145,355 | D | ↗ |
| 2026-01-22 | Cohlhepp Ryan | Director / Officer | S-Sale | D | Common Stock | 3,828 | 18.10 | 69.3K | 210,164 | D | ↗ |
| 2026-01-15 | Cohlhepp Ryan | Director / Officer | S-Sale | D | Common Stock | 149 | 18.02 | 2.7K | 213,992 | D | ↗ |
| 2025-12-26 | Raben David | Officer | M-Exempt | D | Stock Option (Right to Buy) | 19,789 | 3.79 | 75.0K | 98,987 | D | ↗ |
| 2025-12-26 | Cohlhepp Ryan | Director / Officer | M-Exempt | A | Common Stock | 25,000 | 4.44 | 110.9K | 214,141 | D | ↗ |
| 2025-12-22 | Hyep Ivan | Officer | M-Exempt | A | Common Stock | 9,200 | 3.79 | 34.9K | 154,555 | D | ↗ |
| 2025-12-16 | Mazumdar Claire | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 29,500 | 5.45 | 160.9K | 565,512 | D | ↗ |
| 2025-12-15 | Cohlhepp Ryan | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,000 | 3.79 | 30.3K | 141,334 | D | ↗ |
| 2025-11-25 | Raben David | Officer | S-Sale | D | Common Stock | 906 | 18.84 | 17.1K | 35,497 | D | ↗ |
| 2025-11-24 | Raben David | Officer | S-Sale | D | Common Stock | 5,500 | 18.45 | 101.5K | 35,497 | D | ↗ |
| 2025-11-24 | Mazumdar Claire | Director / Officer | M-Exempt | A | Common Stock | 41,163 | 3.79 | 156.0K | 351,055 | D | ↗ |
| 2025-11-24 | Hyep Ivan | Officer | M-Exempt | D | Stock Option (Right to Buy) | 17,795 | 3.79 | 67.4K | 98,184 | D | ↗ |
| 2025-11-21 | Hyep Ivan | Officer | M-Exempt | D | Stock Option (Right to Buy) | 605 | 3.79 | 2.3K | 115,979 | D | ↗ |
| 2025-11-21 | Cohlhepp Ryan | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,000 | 3.79 | 30.3K | 149,334 | D | ↗ |
| 2025-10-15 | Mazumdar Claire | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 13,289 | 3.79 | 50.4K | 301,373 | D | ↗ |
| 2025-10-15 | Cohlhepp Ryan | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,000 | 3.79 | 30.3K | 157,334 | D | ↗ |
| 2025-10-13 | Mazumdar Claire | Director / Officer | M-Exempt | A | Common Stock | 11,445 | 3.79 | 43.4K | 321,337 | D | ↗ |
| 2025-10-09 | Raben David | Officer | M-Exempt | D | Stock Option (Right to Buy) | 22,000 | 3.79 | 83.4K | 128,870 | D | ↗ |
| 2025-10-09 | Hyep Ivan | Officer | M-Exempt | A | Common Stock | 6,415 | 3.79 | 24.3K | 151,770 | D | ↗ |
| 2025-10-08 | Hyep Ivan | Officer | M-Exempt | A | Common Stock | 5,627 | 3.79 | 21.3K | 150,982 | D | ↗ |
| 2025-10-07 | Hyep Ivan | Officer | M-Exempt | A | Common Stock | 18,244 | 3.79 | 69.1K | 163,599 | D | ↗ |
| 2025-10-07 | Cohlhepp Ryan | Director / Officer | M-Exempt | A | Common Stock | 8,000 | 3.79 | 30.3K | 213,541 | D | ↗ |
| 2025-10-06 | Hyep Ivan | Officer | S-Sale | D | Common Stock | 6,514 | 18.17 | 118.4K | 145,355 | D | ↗ |
| 2025-10-06 | Cohlhepp Ryan | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 24,000 | 3.79 | 91.0K | 173,334 | D | ↗ |
| 2025-09-29 | Meisner Lara | Officer | M-Exempt | D | Stock Option (Right to Buy) | 33,807 | 9.24 | 312.5K | 101,423 | D | ↗ |
| 2025-09-15 | Meisner Lara | Officer | M-Exempt | A | Common Stock | 15,829 | 5.45 | 86.3K | 15,829 | D | ↗ |
| 2025-06-16 | Meisner Lara | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,085 | 5.45 | 33.2K | 60,854 | D | ↗ |
| 2025-06-09 | Simson Jake | Director | A-Award | A | Stock Option (Right to Buy) | 23,746 | 11.48 | 272.6K | 23,746 | D | ↗ |
| 2025-06-09 | Robertson Scott M. | Director | A-Award | A | Stock Option (Right to Buy) | 23,746 | 11.48 | 272.6K | 23,746 | D | ↗ |
| 2025-06-09 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 23,746 | 11.48 | 272.6K | 23,746 | I | ↗ |
| 2025-06-09 | POWELL MICHAEL | Director | A-Award | A | Stock Option (Right to Buy) | 23,746 | 11.48 | 272.6K | 23,746 | D | ↗ |
| 2025-06-09 | Mazumdar-Shaw Kiran | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 23,746 | 11.48 | 272.6K | 23,746 | D | ↗ |
| 2025-06-09 | LONBERG NILS | Director | A-Award | A | Stock Option (Right to Buy) | 23,746 | 11.48 | 272.6K | 23,746 | D | ↗ |
| 2025-06-09 | Haviland Kate | Director | A-Award | A | Stock Option (Right to Buy) | 23,746 | 11.48 | 272.6K | 23,746 | D | ↗ |
| 2025-06-09 | Bowden Christopher | Director | A-Award | A | Stock Option (Right to Buy) | 23,746 | 11.48 | 272.6K | 23,746 | D | ↗ |
| 2025-03-14 | Meisner Lara | Officer | M-Exempt | D | Stock Option (Right to Buy) | 48,720 | 5.45 | 265.5K | 107,187 | D | ↗ |
| 2024-09-17 | Flynn James E | 10% Owner | P-Purchase | A | Common Stock | 35,000 | 18.00 | 630.0K | 897,587 | — | ↗ |
| 2024-09-16 | TPG GP A, LLC | 10% Owner | C-Conversion | D | Series C Preferred Stock | 18,121,194 | 0.00 | — | 0 | — | ↗ |
| 2024-09-16 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 152,480 | 18.00 | 2.74M | 2,652,575 | — | ↗ |
| 2024-09-16 | Mazumdar-Shaw Kiran | Director / 10% Owner | C-Conversion | A | Common Stock | 432,736 | 0.00 | — | 432,736 | — | ↗ |
| 2024-09-16 | FMR LLC | Other | C-Conversion | A | Common Stock | 712,430 | 0.00 | — | 723,248 | — | ↗ |
| 2024-09-16 | FIL Ltd | Other | C-Conversion | D | Series C Preferred Stock | 352,876 | 0.00 | — | 0 | — | ↗ |
| 2024-09-16 | Biocon Ltd | 10% Owner | C-Conversion | D | Series Seed Redeemable Convertible Preferred Stock | 9,990,144 | 0.00 | — | 0 | — | ↗ |
| 2024-09-12 | TPG GP A, LLC | 10% Owner | — | I | Series C Preferred Stock | 1,960,425 | 0.00 | — | 0 | — | ↗ |
| 2024-09-12 | Simson Jake | Director | A-Award | A | Stock Option (Right to Buy) | 23,746 | 18.00 | 427.4K | 23,746 | — | ↗ |
| 2024-09-12 | Robertson Scott M. | Director | — | D | Stock Option (Right to Buy) | 59,501 | 3.79 | 225.5K | 0 | — | ↗ |
| 2024-09-12 | Raben David | Officer | — | D | Common Stock | 0 | 0.00 | — | 35,497 | — | ↗ |
| 2024-09-12 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 23,746 | 18.00 | 427.4K | 23,746 | — | ↗ |
| 2024-09-12 | POWELL MICHAEL | Director | — | D | Stock Option (Right to Buy) | 59,501 | 9.24 | 549.8K | 0 | — | ↗ |
| 2024-09-12 | NG CAROLYN | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-12 | Meisner Lara | Officer | — | D | Stock Option (Right to Buy) | 135,230 | 9.24 | 1.25M | 0 | — | ↗ |
| 2024-09-12 | Mazumdar-Shaw Kiran | Director / 10% Owner | — | I | Series Seed Redeemable Convertible Preferred Stock | 432,736 | 0.00 | — | 0 | — | ↗ |
| 2024-09-12 | Mazumdar Claire | Director / Officer | — | D | Stock Option (Right to Buy) | 99,315 | 4.10 | 407.2K | 0 | — | ↗ |
| 2024-09-12 | LONBERG NILS | Director | — | D | Common Stock | 0 | 0.00 | — | 29,991 | — | ↗ |
| 2024-09-12 | Hyep Ivan | Officer | — | D | Common Stock | 0 | 0.00 | — | 145,355 | — | ↗ |
| 2024-09-12 | Haviland Kate | Director | — | D | Common Stock | 0 | 0.00 | — | 7,437 | — | ↗ |
| 2024-09-12 | Flynn James E | 10% Owner | — | I | Series C Preferred Stock | 862,587 | 0.00 | — | 0 | — | ↗ |
| 2024-09-12 | FMR LLC | 10% Owner | — | I | Series B Preferred Stock | 712,430 | 0.00 | — | 0 | — | ↗ |
| 2024-09-12 | FIL Ltd | 10% Owner | — | I | Series Seed Preferred Stock | 54,092 | 0.00 | — | 0 | — | ↗ |
| 2024-09-12 | Cohlhepp Ryan | Officer | — | D | Stock Option (Right to Buy) | 513,874 | 9.24 | 4.75M | 0 | — | ↗ |
| 2024-09-12 | Bowden Christopher | Director | — | D | Stock Option (Right to Buy) | 59,501 | 9.24 | 549.8K | 0 | — | ↗ |
| 2024-09-12 | Biocon Ltd | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 115,757 | — | ↗ |
Executive team
Top executives
Shares Outstanding
54.78M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Claire Mazumdar, Ph.D. Chief Executive Officer | 625.0K | — | — | — | 292.2K | 10.5K | 927.7K | 0.00% | ↗ |
| 2 | 2025 | Ryan Cohlhepp, Pharm.D. President and Chief Operating Officer | 588.0K | 10.0K | — | — | 249.9K | 10.5K | 858.4K | 0.00% | ↗ |
| 3 | 2025 | David Raben, M.D. Chief Medical Officer | 525.0K | 5.0K | — | — | 170.6K | 8.5K | 709.2K | 0.00% | ↗ |
| 4 | 2024 | Claire Mazumdar, Ph.D. Chief Executive Officer | 517.5K | 287.0K | — | 8.09M | 10.0K | 15.3K | 8.92M | 90.70% | ↗ |
| 5 | 2024 | Claire Mazumdar, Ph.D. M.B.A. Chief Executive Officer | 517.5K | 287.0K | — | 8.09M | 10.0K | 15.3K | 8.92M | 90.70% | ↗ |
| 6 | 2024 | Ryan Cohlhepp, Pharm.D. President and Chief Operating Officer | 517.5K | 278.0K | — | 3.64M | 10.0K | 20.3K | 4.47M | 81.52% | ↗ |
| 7 | 2024 | Ivan Hyep, M.B.A Chief Financial Officer | 438.1K | 457.0K | — | 2.68M | — | 20.3K | 3.60M | 74.56% | ↗ |
| 8 | 2023 | Claire Mazumdar, Ph.D. M.B.A. Chief Executive Officer | 450.0K | 180.0K | — | 3.89M | 20.0K | — | 4.54M | 85.69% | ↗ |
| 9 | 2023 | Ryan Cohlhepp, Pharm.D. President and Chief Operating Officer | 450.0K | 190.0K | — | 2.50M | 20.0K | — | 3.16M | 79.11% | ↗ |
| 10 | 2023 | Ivan Hyep, M.B.A Chief Financial Officer | 350.0K | 247.5K | — | 1.88M | — | — | 2.48M | 75.91% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Claire Mazumdar Clemon | Chief Executive Officer & Director | 927.7K | female |
| Ivan Hyep | CFO & Treasurer | 915.4K | male |
| Ryan Cohlhepp | President, Chief Operating Officer & Director | 858.4K | male |
| David Raben | Chief Medical Officer | 709.2K | — |
| Lara S. Meisner | Chief Legal Officer, Compliance Officer & Corporate Secretary | — | female |
| Pauline Dufresne | Chief People Officer | — | female |
| Rachel Salazar | SVP of R&D Strategy and Operations | — | female |
| Sathish Hasige | Senior Vice President and Head of Technical Operations & Supply Chain | — | female |
| Angela Windt | Vice President & Head of Regulatory Affairs | — | female |
| Tanya Green | Chief Development Officer | — | female |
| Jean-Paul Rodrique | Senior Vice President & Global Head of Quality Assurance | — | male |
| Jeltje Schulten | Senior Vice President of Clinical & Medical Affairs | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BCAX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
